BPMC:NSD-Blueprint Medicines Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 88.88

Change

+0.88 (+1.00)%

Market Cap

USD 4.86B

Volume

0.37M

Average Target Price

USD 97.13 (+9.28%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

USD18.93B 47.64 35.20

ETFs Containing BPMC

Symbol Name Weight Mer Price(Change) Market Cap
RYJ Invesco Raymond James SB-.. 0.00 % 0.82 %

+0.89 (+2.28%)

USD0.11B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+0.20 (+0.49%)

USD0.19B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.95% 62% D- 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.95% 62% D- 71% C-
Trailing 12 Months  
Capital Gain 20.97% 53% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.97% 53% F 71% C-
Trailing 5 Years  
Capital Gain 316.49% 89% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 316.49% 89% B+ 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 49.46% N/A N/A 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.46% N/A N/A 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 63.97% N/A N/A 16% F
Risk Adjusted Return 77.32% N/A N/A 86% B
Market Capitalization 4.86B 94% A 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.39 22% F 15% F
Price / Cash Flow Ratio -17.50 79% C+ 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -67.29% 49% F 19% F
Return on Invested Capital -96.87% 28% F 10% F
Return on Assets -31.24% 43% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.62 17% F 9% F
Short Percent 7.84% 42% F 28% F
Beta 1.03 71% C- 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector